557.07 USD
-1.67 (-0.3%)
557.07 USD
0 (0%)
Taking everything into account, MEDP scores 7 out of 10 in our fundamental rating. MEDP was compared to 57 industry peers in the Life Sciences Tools & Services industry. MEDP has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDP is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make MEDP suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year MEDP was profitable.
MEDP had a positive operating cash flow in the past year.
Each year in the past 5 years MEDP has been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
1.2 Ratios
MEDP has a better Return On Assets (24.70%) than 100.00% of its industry peers.
MEDP has a better Return On Equity (147.46%) than 100.00% of its industry peers.
MEDP has a better Return On Invested Capital (91.45%) than 100.00% of its industry peers.
MEDP had an Average Return On Invested Capital over the past 3 years of 38.75%. This is significantly above the industry average of 13.99%.
The last Return On Invested Capital (91.45%) for MEDP is above the 3 year average (38.75%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
The Profit Margin of MEDP (18.36%) is better than 92.98% of its industry peers.
MEDP's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 21.50%, MEDP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
MEDP's Operating Margin has improved in the last couple of years.
MEDP has a worse Gross Margin (31.11%) than 68.42% of its industry peers.
MEDP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDP is creating value.
Compared to 1 year ago, MEDP has less shares outstanding
MEDP has less shares outstanding than it did 5 years ago.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 7.92 indicates that MEDP is not in any danger for bankruptcy at the moment.
MEDP has a better Altman-Z score (7.92) than 87.72% of its industry peers.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.92 |
ROIC/WACC8.79
WACC10.41%
2.3 Liquidity
MEDP has a Current Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP's Current ratio of 0.57 is on the low side compared to the rest of the industry. MEDP is outperformed by 96.49% of its industry peers.
A Quick Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.57, MEDP is doing worse than 94.74% of the companies in the same industry.
MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.22%, which is quite impressive.
MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 33.22% yearly.
MEDP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.88%.
The Revenue has been growing by 19.62% on average over the past years. This is quite good.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
Based on estimates for the next years, MEDP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.31% on average per year.
The Revenue is expected to grow by 12.31% on average over the next years. This is quite good.
EPS Next Y19.53%
EPS Next 2Y15.31%
EPS Next 3Y13.88%
EPS Next 5Y12.31%
Revenue Next Year19.22%
Revenue Next 2Y15.5%
Revenue Next 3Y13.01%
Revenue Next 5Y12.31%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 38.96, MEDP can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of MEDP is on the same level as its industry peers.
MEDP is valuated rather expensively when we compare the Price/Earnings ratio to 26.22, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 33.17 indicates a quite expensive valuation of MEDP.
MEDP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MEDP is cheaper than 64.91% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.58. MEDP is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.96 | ||
| Fwd PE | 33.17 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDP is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, MEDP is valued cheaply inside the industry as 82.46% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.19 | ||
| EV/EBITDA | 28.86 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MEDP's earnings are expected to grow with 13.88% in the coming years.
PEG (NY)1.99
PEG (5Y)1.17
EPS Next 2Y15.31%
EPS Next 3Y13.88%
5. Dividend
5.1 Amount
No dividends for MEDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
557.07
-1.67 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.26%
Inst Owner Change-6.92%
Ins Owners0.37%
Ins Owner Change-6.92%
Market Cap15.69B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target547.08 (-1.79%)
Short Float %6.06%
Short Ratio4.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)5.24%
PT rev (3m)26.25%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)11.36%
EPS NY rev (1m)0.05%
EPS NY rev (3m)5.36%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.96 | ||
| Fwd PE | 33.17 | ||
| P/S | 6.65 | ||
| P/FCF | 23.19 | ||
| P/OCF | 22.06 | ||
| P/B | 53.44 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.86 |
EPS(TTM)14.3
EY2.57%
EPS(NY)16.79
Fwd EY3.01%
FCF(TTM)24.02
FCFY4.31%
OCF(TTM)25.25
OCFY4.53%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)1.99
PEG (5Y)1.17
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 7.92 |
F-Score8
WACC10.41%
ROIC/WACC8.79
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.53%
EPS Next 2Y15.31%
EPS Next 3Y13.88%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.22%
Revenue Next 2Y15.5%
Revenue Next 3Y13.01%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.32%
EBIT Next 3Y15.76%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
What is the valuation status of MEDPACE HOLDINGS INC (MEDP) stock?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
How profitable is MEDPACE HOLDINGS INC (MEDP) stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for MEDP stock?
The Earnings per Share (EPS) of MEDPACE HOLDINGS INC (MEDP) is expected to grow by 19.53% in the next year.